Clinical trials: Rituximab
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with…
- Trial name
- NCT07189065
- Testing
- Rocbrutinib, Bendamustine, Rituximab
- Where
- 41 sites in China
- Volunteers
- 150 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
NMOSD
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain.
- Trial name
- BEST-NMOSD (NCT07010302)
- Testing
- Rituximab (R), Eculizumab (Soliris®), Ravulizumab
- Where
- 3 sites in United States, Germany
- Volunteers
- 540 people
- Sponsor
- Massachusetts General Hospital
Anti-NMDAR Encephalitis
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
- Trial name
- IANMDAR (NCT03274375)
- Testing
- IA session, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma, B-cell, Diffuse
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell…
- Trial name
- NCT03900377
- Testing
- SyB L-0501RI
- Where
- 14 sites in Japan
- Volunteers
- 37 people
- Sponsor
- SymBio Pharmaceuticals
Renal Transplantation
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00214266
- Testing
- Campath 1H®, Rituximab, mycophenolate mofetil
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Lymphoma
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving…
- Trial name
- NCT00450801
- Testing
- Rituximab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Lymphomas
R Retreatment in 1st Relapsed DLBCL
It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to receive 3 cycles of RICE as salvage therapy.
- Trial name
- NCT00980304
- Testing
- Rituximab
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Leukemia
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00343447
- Testing
- autologous tumor cell vaccine, rituximab, cyclophosphamide
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma, Mantle-Cell
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.
- Trial name
- VEGA (NCT05564052)
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 66 sites in Brazil, Czechia and 11 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
High-risk Aggressive Lymphoma After Auto-HSCT
Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma
Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.
- Trial name
- NCT03695055
- Testing
- Maintenance therapy post-HSCT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fujian Medical University
Granulomatous and Lymphocytic Interstitial Lung Disease
Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency
This phase II study will assess the effect of a treatment combination of Rituximab and azathioprine in patients with Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) compared to placebo, based on change in lung…
- Trial name
- NCT02789397
- Testing
- Rituximab (RTX) and Azathioprine (AZA)
- Sponsor
- Medical College of Wisconsin
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT00026182
- Testing
- rituximab, recombinant interleukin-12, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphoma
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a brief chemoimmunotherapy with the combination of Rituximab + Bendamustine + Mitoxantrone in elderly patients with advanced stage…
- Trial name
- FLE09 (NCT01523860)
- Testing
- Rituximab, Mitoxantrone, Bendamustine
- Where
- 37 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B-Cell Lymphoma
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The purpose of this study is to evaluate the efficacy and safety of orelabrutinib combined with rituximab，followed by orelabrutinib combined with R-CHOP-like regimen for newly diagnosed untreated Non-GCB DLBCL Patients
- Trial name
- NCT05498259
- Testing
- Orelabrutinib, Rituximab, CHOP-like Regimen
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma, B-cell Lymphoma
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Sometimes researchers change the DNA (genetic material in cells) of donated T cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient…
- Trial name
- NCT00968760
- Testing
- Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma.
- Conditions
- Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
- Trial name
- NCT07583810
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Diffuse Large B-cell Lymphoma
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma
- Trial name
- NCT06594640
- Testing
- Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX)
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed…
- Trial name
- NCT06205290
- Testing
- Liso-cel, Idelalisib, Rituximab
- Where
- 48 sites in United States, Austria and 9 more
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Lymphoma, B Cell
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in…
- Trial name
- NCT00210379
- Testing
- rituximab, CHOP, intrathecal methotrexate
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)